Sandbox:Javaria: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 24: Line 24:
:❑ [[Bloody stool]]
:❑ [[Bloody stool]]
:❑ [[Weight loss]]
:❑ [[Weight loss]]
:❑ [[Vaginal discharge]]
:❑ [[Penile discharge]]
:❑ [[Jaundice]]
:❑ [[Jaundice]]
:❑ [[Mal-digestion]]
:❑ [[Flatulence]]
:❑ [[Fatigue]]
:❑ [[Fatigue]]
:❑ Recent [[trauma]]
:❑ Recent [[trauma]]
Line 34: Line 30:
'''Detailed history:'''<br>
'''Detailed history:'''<br>
:❑ Age (Patients above 50 years old are more likely to have severe diseases or cancers, such as ruptured [[abdominal aortic aneurysm]] or [[colon cancer]])
:❑ Age (Patients above 50 years old are more likely to have severe diseases or cancers, such as ruptured [[abdominal aortic aneurysm]] or [[colon cancer]])
:❑ Past medical history  
:❑ Past medical history ([[Hepatitis B|Hep B]], [[Hepatitis C|hep C]], [[NASH]], [[Alcoholic Hepatitis|alcoholic hep]] all predispose to [[HCC]])
:❑ Past surgical history (for previous abdominal surgeries)
:❑ Past surgical history (for previous abdominal surgeries)
:❑ Menstrual and contraceptive history (pregnancy should be excluded in all women of childbearing age with abdominal mass)
:❑ Menstrual and contraceptive history (pregnancy should be excluded in all women of childbearing age with abdominal mass)
:❑ Social history (alcohol abuse predispose to pancreatitis and hepatitis, smoking also predisposes to different types of cancers, eg. cancer bladder, which may cause abdominal pain)
:❑ Social history (alcohol abuse predispose to [[pancreatitis]] and [[hepatitis]], smoking also predisposes to [[AAA]] and [[cancer]]s, e.g. [[bladder cancer]])
:❑ Occupational history (exposure to chemicals or toxins)
:❑ Occupational history (exposure to chemicals or toxins)
:❑ Travel history  
:❑ Travel history (recent foreign travel/ drinking of unfiltered water increases risk for [[echinococcus]] or [[entamoeba]] infection).
:❑ Medications (for over the counter drugs as</div>}}
:❑ Family history ([[polycystic kidney disease]]
:❑ Medications (30 and 50 years old women with longstanding [[OCP]] use, may suspect [[hepatic adenoma]]</div>}}
{{familytree | | | | | | | | | | | | | | |!| | | | | | | | |}}
{{familytree | | | | | | | | | | | | | | |!| | | | | | | | |}}
{{familytree | | | | | | | | | | | | | | A02 | | | | | | A02= <div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Examine the patient:''' <br>  
{{familytree | | | | | | | | | | | | | | A02 | | | | | | A02= <div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Examine the patient:''' <br>  
❑ Vital signs<br>
❑ Vital signs<br>
:❑ [[Temperature]]<br>
:❑ [[Temperature]] ([[fever]] may point to [[abscess]] or other infectious causes of mass<br>
:❑ [[Heart rate]] ([[tachycardia]]) <br>
:❑ [[Heart rate]] ([[tachycardia]]) <br>
:❑ [[Blood pressure]] ([[hypotension]])<br>
:❑ [[Blood pressure]] ([[hypotension]])<br>
Line 98: Line 95:
{{familytree/end}}
{{familytree/end}}


Table illustrates common imaging findings in particular disease.<ref name="pmid10524843">{{cite journal |vauthors=Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y |title=Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI |journal=J Comput Assist Tomogr |volume=23 |issue=5 |pages=670–7 |date=1999 |pmid=10524843 |doi=10.1097/00004728-199909000-00004 |url=}}</ref><ref name="pmid22895392">{{cite journal |vauthors=Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H |title=Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update |journal=Gut |volume=61 |issue=12 |pages=1657–69 |date=December 2012 |pmid=22895392 |doi=10.1136/gutjnl-2011-301748 |url=}}</ref><ref name="pmid28229074">{{cite journal |vauthors=Olthof SC, Othman A, Clasen S, Schraml C, Nikolaou K, Bongers M |title=Imaging of Cholangiocarcinoma |journal=Visc Med |volume=32 |issue=6 |pages=402–410 |date=December 2016 |pmid=28229074 |pmc=5290452 |doi=10.1159/000453009 |url=}}</ref>
Table illustrates common imaging findings and management of stabke abdominal masses.<ref name="pmid10524843">{{cite journal |vauthors=Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y |title=Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI |journal=J Comput Assist Tomogr |volume=23 |issue=5 |pages=670–7 |date=1999 |pmid=10524843 |doi=10.1097/00004728-199909000-00004 |url=}}</ref><ref name="pmid22895392">{{cite journal |vauthors=Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H |title=Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update |journal=Gut |volume=61 |issue=12 |pages=1657–69 |date=December 2012 |pmid=22895392 |doi=10.1136/gutjnl-2011-301748 |url=}}</ref><ref name="pmid28229074">{{cite journal |vauthors=Olthof SC, Othman A, Clasen S, Schraml C, Nikolaou K, Bongers M |title=Imaging of Cholangiocarcinoma |journal=Visc Med |volume=32 |issue=6 |pages=402–410 |date=December 2016 |pmid=28229074 |pmc=5290452 |doi=10.1159/000453009 |url=}}</ref>
{| style="border: 2px solid #4479BA; align="left"
{| style="border: 2px solid #4479BA; align="left"
! style="width: 100px; background: #4479BA;" | {{fontcolor|#FFF|Cause of abdominal mass}}
! style="width: 100px; background: #4479BA;" | {{fontcolor|#FFF|Cause of abdominal mass}}
Line 105: Line 102:
! style="width: 300px; background: #4479BA;" | {{fontcolor|#FFF|'''MRI'''}}
! style="width: 300px; background: #4479BA;" | {{fontcolor|#FFF|'''MRI'''}}
! style="width: 300px; background: #4479BA;" | {{fontcolor|#FFF|'''PET scan'''}}
! style="width: 300px; background: #4479BA;" | {{fontcolor|#FFF|'''PET scan'''}}
! style="width: 300px; background: #4479BA;" | {{fontcolor|#FFF|'''Management'''}}
|-
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Hepatic cyst]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Hepatic cyst]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Reserved for more complicated cases.
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Reserved for more complicated cases.
For more information [[Hepatic cysts|click here]]
For more information [[Hepatic cysts|click here]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Most useful initial test.
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |  
Assess cyst size, type, location within the liver, type, and anatomic relations with surroundings.
*Most useful initial test.
|
*Assess cyst size, type, location within the liver, type, and anatomic relations with surroundings.
*Follow-up with [[US]] only if cyst id >4 cm.
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
*Rule out [[infection]] and [[malignancy]]
*[[Fever]] + [[cyst]]= suspect [[pyogenic liver abscess]]/ other infection.
*An asymptomatic simple cyst does not require treatment.
*Symptomatic cyst requires [[sclerotherapy]]/ wide unroofing surgery.
*[[Echinococcosis]] ([[anthelmintic]]s/ and surgery), [[amebic liver abscess]] ([[metronidazole]]), [[pyogenic liver abscess]] ([[Pyogenic liver abscess medical therapy|antibiotic]] + percutaneous drainage).
*[[Cystadenoma]] (surgically removed/ partial hepatectomy)
*Cystadenocarcinoma (hepatic lobectomy/ partial hepatectomy)
|-
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Hemangioma]]s  
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Hemangioma]]s  
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Asymmetric peripheral enhancement on IV contrast (diagnostic potential)
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Asymmetric peripheral enhancement on IV contrast (diagnostic potential)
|
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |  
|
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
|  style="padding: 0 5px; background: #F5F5F5; text-align: left;"| Biopsy is NOT recommended due to bleeding risk
Majority of patients do not require intervention.
|-
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Hepatic adenoma]]s
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Hepatic adenoma]]s
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |  Well-circumscribed hypo-intense lesions.
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |  Well-circumscribed hypo-intense lesions.
|
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
|
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Malignant potential and bleeding risk
[[Discontinue|D/C]] [[OCP]] may lead to involution
>4 cm [[hepatic adenoma|adenoma]] requires surgical resection.
|-
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Hepatocellular carcinoma]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Hepatocellular carcinoma]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Diffuse enhancement with arterial phase contrast, and then washout during delayed venous images.
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | With IV contrast, diffuse enhancement with arterial phase contrast, and then washout during delayed venous images.
|
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
|
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
*Resection (small single lesions, no/limited cirrhosis)/ liver transplant (advanced [[cirrhosis]] but no extrahepatic disease.
*If a [[patient]] with [[liver cirrhosis|cirrhosis]] presents with a >1cm liver mass, pursue a definitive diagnosis to rule out HCC.
*Non-surgical transarterial chemoembolization (TACE) and radiofrequency ablation (RFA).
*[[Sorafenib]] (a [[tyrosine kinase inhibitor]] if patient is not a candidate for resection/ transplant.
|-
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Focal nodular hyperplasia]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Focal nodular hyperplasia]]
Line 133: Line 155:
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Reassurae and observe (no malignant potential)
|-
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Cholangiocarcinoma]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Cholangiocarcinoma]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Lesion occurs in the periphery of [[liver]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |  
Primary staging: Higher [[sensitivity|Sn]] in detecting extrahepatic invasion and vascular involvement.  
*Lesion occurs in the periphery of [[liver]]
*Primary staging: Higher [[sensitivity|Sn]] in detecting extrahepatic invasion and vascular involvement.  
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Modality of choice for [[diagnosis]] and [[staging]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |Modality of choice for [[diagnosis]] and [[staging]]
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Surgical resection with negative margin.
Contrast enhancement patterns vary based on tumour size, composition and structure
|-
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Metastatsis
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Hypo-intense on venous phase contrast. CT does not reliably detect lesions smaller than 1 cm.
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
*[[PET scan]] is more [[sensitivity|Sn]] than CT for detecting hepatic metastases and can detect lesions < 1 cm.
*Metastatic lesions appear as T1 weighted hypointense and T2 weighted hyper-intense images.
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |  
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |  
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
*Surgical resection of hepatic metastases after appropriate selection based on survival benefit.
*Radiofrequency ablation if hepatic resection is not possible.
*A multidisciplinary approach is required.
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
|-
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" |
Line 152: Line 187:
|-
|-
|}
|}
AFP level above 500 mg/dL should raise concern for the presence of HCC.

Revision as of 19:07, 16 August 2020


Abbreviations: ACS: Acute coronary syndrome; AAA: Abdominal aortic aneurysm; RUQ: Right upper quadrant; RLQ: Right lower quadrant; LUQ: Left upper quadrant; LLQ: Left lower quadrant

 
 
 
 
 
 
 
 
 
 
 
 
 
Abdominal mass


Associated pain:

❑ Site (eg, a particular quadrant or diffuse, a change in location may reflect progression of the disease
❑ Onset (eg, sudden, gradual)
❑ Quality (eg, dull, sharp, colicky, waxing and waning)
❑ Aggravating and relieving factors (e.g, Is the pain related to your meals?)
❑ Intensity (scale of 0-10/ 0-5 with the maximum number; 10/5 being the worst pain of life)
❑ Time course (eg, hours versus weeks, constant or intermittent)
❑ Radiation (eg, to the shoulder, back, flank, groin, or chest)

Associated symptoms

Shortness of breath
Altered mental status
Nausea & vomiting
Diaphoresis
Fever
Hematuria
Anorexia
Bloody stool
Weight loss
Jaundice
Fatigue
❑ Recent trauma
❑ Symptoms suggestive of sepsis

Detailed history:

❑ Age (Patients above 50 years old are more likely to have severe diseases or cancers, such as ruptured abdominal aortic aneurysm or colon cancer)
❑ Past medical history (Hep B, hep C, NASH, alcoholic hep all predispose to HCC)
❑ Past surgical history (for previous abdominal surgeries)
❑ Menstrual and contraceptive history (pregnancy should be excluded in all women of childbearing age with abdominal mass)
❑ Social history (alcohol abuse predispose to pancreatitis and hepatitis, smoking also predisposes to AAA and cancers, e.g. bladder cancer)
❑ Occupational history (exposure to chemicals or toxins)
❑ Travel history (recent foreign travel/ drinking of unfiltered water increases risk for echinococcus or entamoeba infection).
❑ Family history (polycystic kidney disease
❑ Medications (30 and 50 years old women with longstanding OCP use, may suspect hepatic adenoma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:

❑ Vital signs

Temperature (fever may point to abscess or other infectious causes of mass
Heart rate (tachycardia)
Blood pressure (hypotension)
Respiratory rate (tachypnea)

❑ Skin

Diaphoresis
Pallor
Jaundice
Dehydration

❑ Inspection

❑ If the patient is lying still in bed with knees bent, this is suggestive of organ rupture and resulting peritonitis
❑ Signs of previous surgery
❑ Abdominal pulsations
❑ Signs of systemic disease e.g.
Pallor, suggestive of bleeding
Spider angiomata, suggestive of cirrhosis

Auscultation

❑ Abdominal crepitations
❑ Reduced bowel sounds
❑ Bruit, suggestive of abdominal aortic aneurysm

❑ Palpation

❑ Rigidity
Guarding
❑ Abdominal tenderness
Distension
❑ Detection of masses on palpating the abdomen
Carnett's sign

Pelvic exam in females
Testicular examination in males
❑ Cardiovascular system
❑ Respiratory system
❑ Anorectal (bleeding)
Signs of sepsis: tachycardia, decreased urination, and hyperglycemia, confusion, metabolic acidosis with compensatory respiratory alkalosis, hypotension, decreased systemic vascular resistance, and coagulation dysfunctions

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider extraabdominal differential diagnosis:
❑ aaaa
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess hemodynamic stability
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If the patient is unstable,
Stabilize the patient:
❑ Establish two large-bore intravenous peripheral lines
NPO until the patient is stable
❑ Supportive care (fluids and electrolyes as required)
❑ Place nasogastric tube if there is bleeding, obstruction, significant nausea or vomiting
❑ Place foley catheter to monitor volume status
❑ Cardiac monitoring
❑ Supplemental oxygen as needed
❑ Administer early antibiotics if indicated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If the patient is stable,
Order laboratory tests:
Pregnancy test (required in women of child-bearing age)
CBC, Hematocrit
Urinalysis
ESR
ABG
D dimer
Serum lactate
BMP (urea, creatinine, serum electrolytes, BSL)
Amylase
Lipase
Triglyceride
Liver function tests (total bilirubin, direct bilirubin, albumin, AST, ALT, Alkaline phosphatase, GGT)

Order imaging studies:
❑ Order urgent trans abdominal ultrasound (TAUSG)
Abdominal CT
ECG
MRCP
Abdominal x-ray
Angiography
❑ Diagnostic paracentesis


*Order the tests to rule in a suspected diagnosis
or to assess a case of unclear etiology

*In case of elderly patients, immunocompromised
or those unable to provide a comprehensive
history, order broader range of tests
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signs of peritonitis or shock
Fever
❑ Abdominal tenderness
❑ Abdominal gaurding
❑ Rebound tenderness (blumberg sign)
❑ Diffuse abdominal rigidity
Confusion
❑ Weakness
❑ Low blood pressure
❑ Decreased urine output
❑ Tachycardia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Table illustrates common imaging findings and management of stabke abdominal masses.[1][2][3]

Cause of abdominal mass CT scan Ultrasound MRI PET scan Management
Hepatic cyst Reserved for more complicated cases.

For more information click here

  • Most useful initial test.
  • Assess cyst size, type, location within the liver, type, and anatomic relations with surroundings.
  • Follow-up with US only if cyst id >4 cm.
Hemangiomas Asymmetric peripheral enhancement on IV contrast (diagnostic potential) Biopsy is NOT recommended due to bleeding risk

Majority of patients do not require intervention.

Hepatic adenomas Well-circumscribed hypo-intense lesions. Malignant potential and bleeding risk

D/C OCP may lead to involution >4 cm adenoma requires surgical resection.

Hepatocellular carcinoma With IV contrast, diffuse enhancement with arterial phase contrast, and then washout during delayed venous images.
  • Resection (small single lesions, no/limited cirrhosis)/ liver transplant (advanced cirrhosis but no extrahepatic disease.
  • If a patient with cirrhosis presents with a >1cm liver mass, pursue a definitive diagnosis to rule out HCC.
  • Non-surgical transarterial chemoembolization (TACE) and radiofrequency ablation (RFA).
  • Sorafenib (a tyrosine kinase inhibitor if patient is not a candidate for resection/ transplant.
Focal nodular hyperplasia Well-circumscribed mass with central stellate scar. With IV contrast hyperintense on

arterial phase and isodense on venous phase.

Reassurae and observe (no malignant potential)
Cholangiocarcinoma
  • Lesion occurs in the periphery of liver
  • Primary staging: Higher Sn in detecting extrahepatic invasion and vascular involvement.
Modality of choice for diagnosis and staging Surgical resection with negative margin.
Metastatsis Hypo-intense on venous phase contrast. CT does not reliably detect lesions smaller than 1 cm.
  • PET scan is more Sn than CT for detecting hepatic metastases and can detect lesions < 1 cm.
  • Metastatic lesions appear as T1 weighted hypointense and T2 weighted hyper-intense images.
  • Surgical resection of hepatic metastases after appropriate selection based on survival benefit.
  • Radiofrequency ablation if hepatic resection is not possible.
  • A multidisciplinary approach is required.


AFP level above 500 mg/dL should raise concern for the presence of HCC.

  1. Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y (1999). "Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI". J Comput Assist Tomogr. 23 (5): 670–7. doi:10.1097/00004728-199909000-00004. PMID 10524843.
  2. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H (December 2012). "Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update". Gut. 61 (12): 1657–69. doi:10.1136/gutjnl-2011-301748. PMID 22895392.
  3. Olthof SC, Othman A, Clasen S, Schraml C, Nikolaou K, Bongers M (December 2016). "Imaging of Cholangiocarcinoma". Visc Med. 32 (6): 402–410. doi:10.1159/000453009. PMC 5290452. PMID 28229074.